Nuvalent Inc (NUVL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvalent Inc (NUVL) has a cash flow conversion efficiency ratio of -0.079x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.40 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NUVL defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Nuvalent Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Nuvalent Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nuvalent Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvalent Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hella KGaA Hueck & Co
XETRA:HLE
|
0.175x |
|
Huadian Energy
SHG:600726
|
0.009x |
|
Akbank TAS
IS:AKBNK
|
0.103x |
|
Petronas Chemicals Group Bhd
KLSE:5183
|
0.025x |
|
Yangzhou Yangjie Electronic Technology Co Ltd
SHE:300373
|
0.026x |
|
Verona Pharma plc
F:I9SA
|
0.110x |
|
Brenntag SE
F:BNR
|
0.076x |
|
Enlight Renewable Energy Ltd
TA:ENLT
|
0.041x |
Annual Cash Flow Conversion Efficiency for Nuvalent Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Nuvalent Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see NUVL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.25 Billion | $-275.21 Million | -0.220x | -27.44% |
| 2024-12-31 | $1.07 Billion | $-185.06 Million | -0.173x | -21.51% |
| 2023-12-31 | $700.56 Million | $-99.74 Million | -0.142x | -1.45% |
| 2022-12-31 | $462.98 Million | $-64.97 Million | -0.140x | 0.00% |
| 2021-12-31 | $285.04 Million | $-40.00 Million | -0.140x | -129.40% |
| 2020-12-31 | $-31.32 Million | $-14.95 Million | 0.477x | -14.56% |
| 2019-12-31 | $-17.26 Million | $-9.64 Million | 0.559x | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more